SOURCE: Kalorama Information

Kalorama Information

December 19, 2012 10:19 ET

Market for Kinase Inhibitors Heats Up: Kalorama

NEW YORK, NY--(Marketwire - Dec 19, 2012) - The cancer kinase inhibitor market is estimated at $12.1 billion worldwide for 2012, representing annual revenue growth of 16.9% over 2007. The effectiveness of kinase inhibitors has sparked interest from major pharmaceutical companies, according to the healthcare market research publisher, Kalorama Information. With rising cancer incidence and new products being developed, this trend will likely continue according to Kalorama's new report, The Next Wave in Cancer Treatment - Kinase Inhibitors.

A kinase inhibitor is a drug that specifically blocks the action of one or more protein kinases, enzymes which regulate cell growth in the body. Kinases provide necessary signals to cells in the body when functioning normally, but when mutated, they can cause cells to grow uncontrollably, causing cancer. Inhibitor drugs have been effective in disrupting growth signals in some cancers. Novartis's Gleevec leukemia treatment is among the better-selling products in the category and it competes with Bristol Myer Squibb's Sprycel. As Gleevec faces patent expiration, Novartis is marketing a newer kinase inhibitor called Tasigna which it describes as more effective.

"Several factors contribute to revenue growth for kinase inhibitor products," said Melissa Elder, analyst for Kalorama Information and author of the report. "These include an increasing incidence of cancer resulting from an aging population, accelerated sales of newer products, several promising late stage developments, and increased marketing among product suppliers."

According to the report, the rising incidence of cancer, particularly in the over 50 population, is likely to have a significant impact on all areas of cancer treatment. However, for many cancer types, there remains a significant unmet need for effective treatments. Lung cancer is one such example, as patient survival is less than five years after diagnosis. Traditional therapies have failed to provide adequate treatment for these patients, signifying a need for an alternative treatment plan. Compassionate use has been granted for several therapies in the past and this trend is likely to continue.

The report indicates that cancer affects between 12 and 13 million people worldwide each year, and it is expected to increase to 16 million each year by 2020. Worldwide, approximately 24 million people are living with cancer and nearly 8 million people die each year. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to an 80% death rate for cancer patients in underdeveloped countries.

Manufacturers of cancer therapeutics designed to counter this trends are primarily U.S. and European companies, although a number of Japanese companies have become significant in the marketplace in the past fifteen years. AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer and Roche are among the companies profiled in Kalorama's study.

The full report, The Next Wave in Cancer Treatment - Kinase Inhibitors, contains market forecasts, detailed discussions of kinase inhibitor products and their revenues, and coverage of important trends.

About Kalorama Information
Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact Information